Introduction {#Sec1}
============

Glaucoma is a chronic disease and still a major cause of blindness. Most patients with glaucoma must use ocular hypotensive drugs continuously throughout their life. However, since glaucoma is relatively asymptomatic in the early stage, the low adherence to ophthalmic solutions for anti-glaucoma was reported \[[@CR1]\]. Poor adherence raises the risk of the progression of visual field defects \[[@CR2]\] and also the risk of blindness in glaucoma patients \[[@CR3]\].

Nowadays, although prostaglandin analogs (PGAs) or β-blockers are used in the first-line therapy because of their potent ocular hypotensive effects, there are many patients treated with the concomitant use of two or more drugs \[[@CR4]\]. The concomitant therapy for glaucoma may cause a decrease in the adherence due to complicated dosing regimens, weaken the hypotensive effects with wash-out effects with a short instillation interval (less than 5 min), and cause corneal and/or conjunctival disorders by an increase in the amount and frequency of preservative exposure \[[@CR5]\]. Therefore, a fixed combination therapy, when available, should be preferable to two separate instillations of agents \[[@CR5]\].

A fixed combination of tafluprost (0.0015%) and timolol maleate (0.5%) (Tapcom^®^ combination ophthalmic solution, Santen Pharmaceutical Co., Ltd., Osaka, Japan: Taf--TFC) has been developed for the treatment of glaucoma and ocular hypertension (OH). Three Japanese phase III clinical trials conducted in patients with primary open-angle glaucoma (POAG) or OH have demonstrated that the intraocular pressure (IOP)-lowering effect of Taf--TFC is not inferior to concomitant use of the two active drugs \[[@CR6]\] and is superior to either agent alone \[[@CR6], [@CR7]\]. Based on these findings, Taf--TFC was approved in Japan in 2014, and it is also marketed in Europe as a preservative-free solution (Tapticom, Santen Oy, Finland). However, typically, the patients in the pivotal clinical studies are limited in terms of the type and severity of glaucoma, associated diseases, and concomitant medications. In addition, treatment was administered under stringent control. To obtain more additional information in real-world setting, a post-marketing study needs to be performed using various treatment regimens in a wider variety of patients to evaluate the efficacy and safety of Taf--TFC in routine clinical practice. Accordingly, Santen is currently conducting a long-term observational study with an up to 2-year (more than 1 year) follow-up period in a large population of more than 1000 patients. This report presents the short-term results obtained with Taf--TFC in various clinical settings based on analysis of the data up to 3 months.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

A multicenter, prospective, non-interventional, observational post-marketing study is being conducted in accordance with the requirements of the Japanese regulatory authority (Good Post-Marketing Study Practice, Ministry of Health, Labor and Welfare Ordinance No. 171; December 20, 2004). The study commenced in January 2015 and is scheduled to run until September 2018. Since the protocol was reviewed and approved by the Japanese regulatory authority prior to initiation of the study, approval by the ethics committee at each participating institution was not required.

Patients and Registration {#Sec4}
-------------------------

The inclusion criteria for this study are patients with glaucoma or OH who had not previously been treated with Taf--TFC. A central registration system is used to avoid selection bias. When a patient meets the inclusion criteria, the participating physician registers the patient by facsimile within 2 weeks of prescribing Taf--TFC. Since the Japanese regulatory authority does not require informed consent for post-marketing observational studies, informed consent is not obtained from the patients. The observation period has been set as up to 2 years (more than 1 year) after starting treatment with Taf--TFC. Data are collected over two different periods \[0--3 months, and up to 2 years (more than 1 year) after starting treatment\], including the demographic profile (data were collected from the physician's report), Taf--TFC regimen, previous and concomitant drugs, IOP, objective findings (conjunctival hyperemia and corneal fluorescein staining), dosing compliance, and adverse events. Patients are classified into the following three groups based on previous and concomitant drugs: "Naïve," no previous treatment or concomitant drugs; "Switched," switched to Taf--TFC monotherapy after treatment with at least one previous drug; "Concomitant," addition of or switching to Taf--TFC combined with other anti-glaucoma medications. A 4-point scale is used to determine the conjunctival hyperemia and corneal staining scores: 0, none; 1, mild; 2, moderate; and 3, severe. If adverse events occur, the physician evaluates the causal relationship with Taf--TFC and events for which a causal relationship to Taf--TFC cannot be excluded are classified as adverse drug reactions (ADRs). Data tabulation and analysis were performed using SAS software (Version 9.2, SAS Institute, Cary, NC, USA), with results being expressed as the mean ± standard deviation (SD). The starting point of treatment with Taf--TFC was used as the baseline (0 months). The level of statistical significance was set at 5% (two-sided). The IOP was compared by the paired *t* test, and the scores for objective findings were compared by Wilcoxon's signed-rank sum test, with the *P* value then being calculated.

Results {#Sec5}
=======

Demographic Profile {#Sec6}
-------------------

Data on 439 patients from 100 participating institutions have been analyzed as of December 2015. The demographic and clinical profile of these patients is summarized in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and clinical profileTotalNaïveSwitchedConcomitantNo. of patients analyzed4396728488Sex Male199 (45.3)30 (44.8)125 (44.0)44 (50.0) Female240 (54.7)37 (55.2)159 (56.0)44 (50.0)Age (years) Mean ± SD67.3 ± 13.165.7 ± 14.567.2 ± 13.268.5 ± 11.7 Minimum--maximum21.0--95.030.0--93.021.0--92.035.0--95.0Diagnosis POAG158 (36.0)24 (15.2)90 (57.0)44 (27.8) NTG199 (45.3)33 (16.6)141 (70.9)25 (12.6) PACG22 (5.0)2 (9.1)13 (59.1)7 (31.8) OH35 (8.0)5 (14.3)28 (80.0)2 (5.7) Other types of glaucoma25 (5.7)3 (12.0)12 (48.0)10 (40.0)Baseline IOP (mmHg) Mean ± SD20.0 ± 6.819.1 ± 7.919.5 ± 5.622.5 ± 8.6 Min--max8.0--52.08.0--52.010.0--50.08.0--52.0Ocular complications Yes149 (33.9)32 (47.8)96 (33.8)21 (23.9) No290 (66.1)35 (52.2)188 (66.2)67 (76.1)Systemic complications Yes196 (51.0)27 (50.0)137 (54.2)32 (41.6) No188 (49.0)27 (50.0)116 (45.8)45 (58.4) Unknown55133111*IOP* intraocular pressure, *NTG* normal tension glaucoma, *OH* ocular hypertension, *PACG* primary angle-closure glaucoma, *POAG* primary open-angle glaucoma, *SD* standard deviation

In this patient cohort, 45.3% were male and 54.7% were female, with a mean age of 67.3 ± 13.1 years (range 21--95 years). The diagnosis was POAG (untreated IOP ≥ 21 mmHg) in 36.0%, normal tension glaucoma (NTG, untreated IOP \< 21 mmHg) in 45.3%, primary angle-closure glaucoma (PACG) in 5.0%, OH (untreated IOP ≥ 21 mmHg without glaucomatous optic neuropathy or glaucomatous visual field loss) in 8.0%, and other types of glaucoma in 5.7%. Forty-two patients discontinued the study before 3 months, including 9 patients (21.4%) in whom treatment showed insufficient efficacy (4 patients with POAG, 1 patient each with NTG, OH and angle-closure glaucoma, and 2 patients with other glaucoma type), 14 patients (33.3%) with adverse events (all events were topical ADRs), 13 patients (31.0%) who withdrew from study at their own request, and 6 patients (14.3%) who discontinued for other reasons.

Among the 439 patients, 67 patients (15.3%) were in the "Naïve" group, 284 patients (64.7%) were in the "Switched" group, and 88 patients (20.0%) were in the "Concomitant" group. The characteristics of each group are summarized in Fig. [1](#Fig1){ref-type="fig"}. The three groups did not show any large differences of glaucoma type, age, baseline IOP, and baseline mean deviation (MD) values, although the "Naïve" group had a higher proportion of patients aged 30--39 years and with a baseline IOP of 25 mmHg or over.Fig. 1Background of the three groups. "*Naïve*" no previous treatment or concomitant drugs; "*Switched*" switched to Taf--TFC monotherapy after treatment with at least one previous drug; "*Concomitant*" addition of/switching to Taf--TFC combined with other anti-glaucoma medications. *IOP* intraocular pressure, *MD* mean deviation, *NTG* normal tension glaucoma, *OH* ocular hypertension, *PACG* primary angle-closure glaucoma, *POAG* primary open-angle glaucoma*, Taf--TFC* tafluprost 0.0015%/timolol maleate 0.5% combination ophthalmic solution

Previous medications varied widely in the "switched" group, including PGA monotherapy (*n* = 145, 54.5%), PGA and β-blocker (timolol, carteolol, etc.) concomitant therapy (*n* = 34, 12.8%), β-blocker (timolol, carteolol, etc.) monotherapy (*n* = 28, 10.5%), and monotherapy with another fixed combination of PGA and timolol (PGA--TFC) (*n* = 51, 19.2%).

Adverse Drug Reactions {#Sec7}
----------------------

There were 25 adverse events classified as ADRs in 22 patients (5.01%) (Table [2](#Tab2){ref-type="table"}). ADRs were local (affecting the eye) in 20 events and systemic in 5 events. The major ADRs were conjunctival hyperemia (5 events), blepharitis (4 events), and punctate keratitis (2 events). The serious ADR were recognized in 2 patients (3 events); blood pressure increased, asthenic conditions (physical deconditioning), and chest discomfort (one each).Table 2Adverse drug reactionsNo. of patients analyzed439No. of ADRs^a^25No. of patients with ADRs (%)22 (5.01)System organ classPreferred termEvents (%)Eye disordersAbnormal sensation in eye1 (0.23)Blepharitis4 (0.91)Erythema of eyelid1 (0.23)Eye pain1 (0.23)Eyelid edema1 (0.23)Ocular hyperemia1 (0.23)Photopsia1 (0.23)Punctate keratitis2 (0.46)Vision blurred1 (0.23)Growth of eyelashes1 (0.23)Conjunctival hyperemia5 (1.14)Eye pruritus1 (0.23)Cardiac disordersArrhythmia1 (0.23)Palpitations1 (0.23)General disorders and administration site conditionsAsthenia1 (0.23)Chest discomfort1 (0.23)InvestigationsBlood pressure increased1 (0.23)^a^ADR adverse drug reaction (adverse event possibly related to tafluprost 0.0015%/timolol maleate 0.5% combination ophthalmic solution)

For the case of blood pressure increase, increased blood pressure was observed after 26 days of administration with Taf--TFC who was complicated by hypertension (188/108 mmHg at baseline, 207/138 mmHg at onset). Increased blood pressure was unrecovered (226/142 mmHg) at 3 months of administration with continuing Taf--TFC administration.

The asthenic conditions (physical deconditioning) and the chest discomfort were expressed in the same patient and were both expressed after 15 days of administration with Taf--TFC. By the discontinuation of Taf--TFC drug administration, symptoms were recovered.

The mean hyperemia score was 0.2 ± 0.5 (*n* = 386) at baseline, 0.2 ± 0.4 (*n* = 274) at 1 month, 0.2 ± 0.4 (*n* = 252) at 2 months, and 0.2 ± 0.4 (*n* = 244) at 3 months. There was no significant change in the score during the course of the study. The mean corneal staining score was 0.2 ± 0.4 (*n* = 362) at baseline, 0.2 ± 0.4 (*n* = 256) at 1 month, 0.1 ± 0.4 (*n* = 234) at 2 months, and 0.1 ± 0.4 (*n* = 232) at 3 months. There were no significant changes of these scores at any time.

IOP-Lowering Effect {#Sec8}
-------------------

Of the 439 patients, IOP data were analyzed in 410 patients in whom the IOP was measured both before and after treatment with Taf--TFC. The treatment patterns of these 410 patients are shown in Fig. [2](#Fig2){ref-type="fig"}. Their baseline mean IOP was 17.5 ± 5.0 mmHg (*n* = 410), and mean IOP changed significantly by −3.0 ± 4.2 at 1 month (*n* = 282), −3.0 ± 4.3 at 2 months (*n* = 266), and −3.2 ± 4.3 mmHg at 3 month (*n* = 243) relative to baseline (all *P* \< 0.05, paired-*t* test) (Table [3](#Tab3){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). IOP was significantly reduced in patients with POAG, NTG, and OH. The IOP-lowering effect of Taf--TFC was not influenced by age or sex.Fig. 2Treatment patterns in 410 patients. "*Naïve*" no previous treatment or concomitant drugs; "*Switched*" switched to *Taf--TFC* monotherapy after treatment with at least one previous drug; "*Concomitant*" addition of/switching to *Taf--TFC* combined with other anti-glaucoma medications. *PGA* prostaglandin analog, *β* β-blocker, *PGA--TFC* fixed combination of a prostaglandin analog and timolol, Lat--TFC fixed combination of latanoprost and timolol, *Tra--TFC* fixed combination of travoprost and timolol. *Lat--TFC* latanoprost/timolol combination, *PGA* prostaglandin analogs, *Tra--TFC* travoprost/timolol combination Table 3IOP stratified by treatment patternTreatment patternBaseline1 month2 months3 monthsAll IOP (mmHg)17.5 ± 5.014.6 ± 4.114.5 ± 3.714.4 ± 3.6 IOP change (mmHg)--−3.0 ± 4.2−3.0 ± 4.3−3.2 ± 4.3 No. of patients410282266243 *P* value--\<0.001\<0.001\<0.001Naïve^a^ IOP (mmHg)18.6 ± 6.112.8 ± 3.313.8 ± 3.813.9 ± 3.2 IOP change (mmHg)−4.9 ± 3.3−4.3 ± 3.0−5.1 ± 3.0 No. of patients59453130 *P* value--\<0.001\<0.001\<0.001Switched^b^ IOP (mmHg)17.0 ± 4.215.0 ± 4.214.4 ± 3.514.5 ± 3.7 IOP change (mmHg)--−2.1 ± 2.7−2.5 ± 3.1−2.4 ± 3.1 No. of patients267181174162 *P* value--\<0.001\<0.001\<0.001Concomitant^c^ IOP (mmHg)18.2 ± 6.414.6 ± 4.114.9 ± 4.114.2 ± 3.7 IOP change (mmHg)--−4.5 ± 6.9−3.9 ± 6.9−4.6 ± 6.9 No. of patients84566151 *P* value--\<0.001\<0.001\<0.001*IOP* intraocular pressure, *Taf--TFC* tafluprost 0.0015%/timolol maleate 0.5% combination ophthalmic solution^a^"Naïve," no previous treatment or concomitant drugs^b^"Switched," switched to *Taf--TFC* monotherapy after treatment with at least one previous drug^c^"Concomitant," addition of/switching to *Taf--TFC* combined with other anti-glaucoma medications Fig. 3IOP changes from baseline in 410 patients. "Naïve," no previous treatment or concomitant drugs; "Switched," switched to *Taf--TFC* monotherapy after treatment with at least one previous drug; "Concomitant," addition of/switching to *Taf--TFC* combined with other anti-glaucoma medications. IOP intraocular pressure, *Taf--TFC* tafluprost 0.0015%/timolol maleate 0.5% combination ophthalmic solution

In the "Naïve" group, the mean IOP was 18.6 ± 6.1 mmHg at baseline (*n* = 59), and it was significantly reduced at 1, 2, and 3 months (−4.9 ± 3.3, −4.3 ± 3.0, and −5.1 ± 3.0 mmHg, respectively, *P* \< 0.001, paired *t*-test, Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). In the "Switched" group, mean IOP was 17.0 ± 4.2 mmHg at baseline (*n* = 267), and it was also significantly reduced at 1, 2, and 3 months (−2.1 ± 2.7, −2.5 ± 3.1, and −2.4 ± 3.1 mmHg, respectively, *P* \< 0.001, paired *t*-test, Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). In the "Concomitant" group, mean IOP was 18.2 ± 6.4 mmHg at baseline (*n* = 84), and it likewise showed a significant decrease at 1, 2, and 3 months (−4.5 ± 6.9, −3.9 ± 6.9, and −4.6 ± 6.9 mmHg respectively, *P* \< 0.001, paired t-test, Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}).

In patients switched from PGA monotherapy to Taf--TFC monotherapy, mean IOP was 17.4 ± 4.0 mmHg at baseline (*n* = 137), and it declined significantly at 1, 2, and 3 months after switching (−2.8 ± 2.1, −3.1 ± 3.2, and −2.9 ± 3.3 mmHg, respectively, *P* \< 0.001, paired*t*-test, Table [4](#Tab4){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). The IOP reduction was similar in patients switched from latanoprost, travoprost or tafluprost to Taf--TFC monotherapy (Fig. [5](#Fig5){ref-type="fig"}). Among patients switched from PGA monotherapy, IOP reduction ≥2 mmHg was defined as "improved," change of the IOP within 2 mmHg was defined as "unchanged," and an increase in IOP by ≥2 mmHg was defined as "worse." As a result, 64.3% of patients were "improved," 31.0% were "unchanged," and 4.8% were "worse" (Fig. [6](#Fig6){ref-type="fig"}). At 3 months, improvement was noted in 17 patients (70.8%) switched from latanoprost (*n* = 24), 24 patients (60.0%) switched from tafluprost (*n* = 40), and 5 patients (55.6%) switched from travoprost (*n* = 9).Table 4Intraocular pressure stratified by previous medicationsSwitched fromBaseline1 month2 months3 monthsPGA monotherapy IOP (mmHg)17.4 ± 4.014.4 ± 3.314.1 ± 3.014.2 ± 3.3 IOP change (mmHg)--−2.8 ± 2.1−3.1 ± 3.2−2.9 ± 3.3 No. of patients137958584 *P* value--\<0.001\<0.001\<0.001Latanoprost IOP (mmHg)17.4 ± 4.614.1 ± 3.113.6 ± 2.714.1 ± 3.2 IOP change (mmHg)--−3.2 ± 2.4−3.8 ± 4.3−3.3 ± 2.7 No. of patients46362624 *P* value--\<0.001\<0.001\<0.001Travoprost IOP (mmHg)16.6 ± 3.414.8 ± 3.813.9 ± 3.613.4 ± 3.5 IOP change (mmHg)−2.1 ± 1.6−1.9 ± 1.6−2.8 ± 2.8 No. of patients151099 *P* value--0.0030.0080.016Tafluprost IOP (mmHg)16.7 ± 3.814.3 ± 3.513.6 ± 2.813.9 ± 3.5 IOP change (mmHg)−2.7 ± 2.0−3.1 ± 2.9−2.5 ± 4.0 No. of patients60433840 *P* value--\<0.001\<0.001\<0.001β−blocker monotherapy IOP (mmHg)16.7 ± 3.714.7 ± 3.113.3 ± 3.013.4 ± 3.1 IOP change (mmHg)--−2.5 ± 1.9−2.6 ± 2.5−4.1 ± 2.1 No. of patients25181417 *P* value--\<0.0010.002\<0.001PGA--TFC monotherapy IOP (mmHg)18.0 ± 4.916.6 ± 5.016.4 ± 4.117.0 ± 5.0 IOP change (mmHg)--−1.6 ± 2.2−1.9 ± 2.3−1.3 ± 3.1 No. of patients48283625 *P* value--\<0.001\<0.0010.04Lat--TFC IOP (mmHg)18.0 ± 5.717.4 ± 6.316.9 ± 5.015.2 ± 4.9 IOP change (mmHg)−1.3 ± 2.5−1.9 ± 2.6−1.5 ± 2.5 No. of patients23131613 *P* value--0.080.010.049Tra--TFC IOP (mmHg)18.1 ± 4.115.9 ± 3.716.0 ± 3.418.9 ± 4.7 IOP change (mmHg)−1.8 ± 1.9−1.9 ± 2.2−1.1 ± 3.7 No. of patients25152012 *P* value--0.0020.0010.315Concomitant therapy (PGA, β-blocker) IOP (mmHg)15.1 ± 2.914.9 ± 3.914.5 ± 4.014.4 ± 3.6 IOP change (mmHg)--−0.4 ± 2.7−0.7 ± 3.5−0.4 ± 2.1 No. of patients31222220 *P* value--0.4580.3390.408*IOP* intraocular pressure, *Lat--TFC* latanoprost/timolol combination, *PGA* prostaglandin analogs, *Tra--TFC* travoprost/timolol combination Fig. 4Intraocular pressure changes from baseline in patients stratified by switched medications. "*PGA*" prostaglandin analog (latanoprost, travoprost, tafluprost, bimatoprost, or unoprostone); "*β-blocker*" β-adrenergic receptor antagonist (timolol or carteolol); "*PGA--TFC*" fixed combination of a prostaglandin analog and timolol (latanoprost/timolol or travoprost/timolol); "*concomitant*" concomitant use of a PGA and a β-blocker. *IOP* intraocular pressure, *PGA--TFC* prostaglandin analogs and timolol Fig. 5Intraocular pressure changes from baseline in patients switched from prostaglandin analog monotherapy. *IOP* intraocular pressure Fig. 6Efficacy of tafluprost/timolol fixed combination in patient switched from each prostaglandin analog at 3 months. *PGA* prostaglandin analogs

In patients switched from β-blocker (timolol, carteolol, etc.) monotherapy to Taf--TFC monotherapy, mean IOP was 16.7 ± 3.7 mmHg at baseline (*n* = 25), and it was significantly reduced at 1, 2, and 3 months after switching to Taf--TFC (−2.5 ± 1.9, −2.6 ± 2.5, and −4.1 ± 2.1 mmHg, respectively, *P* \< 0.05, paired *t*-test) (Table [4](#Tab4){ref-type="table"}; Fig. [4](#Fig4){ref-type="fig"}).

In patients switched from PGA and β-blocker (timolol, carteolol, etc.) combined therapy to Taf--TFC monotherapy, mean IOP was 15.1 ± 2.9 mmHg at baseline (*n* = 31) and did not change significantly up to 3 months of Taf--TFC treatment (paired *t*-test, Table [4](#Tab4){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). On the other hand, in patients with switched from other PGA--TFC to Taf--TFC monotherapy, mean IOP was 18.0 ± 4.9 mmHg at baseline, and it was significantly reduced at 1, 2, and 3 months after switching to Taf--TFC (−1.6 ± 2.2, −1.9 ± 2.3, and −1.3 ± 3.1 mmHg, respectively, *P* \< 0.05, paired *t*-test, Table [4](#Tab4){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). The decrease in IOP with Taf--TFC monotherapy was similar in patients switched from the latanoprost/timolol combination (Lat--TFC) or travoprost/timolol combination (Tra--TFC) drug, but a significant reduction was not observed in the former patients at 1 month and in the latter patients at 3 months (Table [4](#Tab4){ref-type="table"}, Fig. [7](#Fig7){ref-type="fig"}). At 3 months, six patients (46.2%) switched from Lat--TFC (*n* = 13) and six patients (50.0%) switched from Tra--TFC (*n* = 12) were classified as "improved" (Fig. [8](#Fig8){ref-type="fig"}).Fig. 7Intraocular pressure changes from baseline in patients switched from a prostaglandin analog/timolol combination. *IOP* intraocular pressure, *Lat--TFC* latanoprost/timolol combination Fig. 8Efficacy of tafluprost/timolol fixed combination in patients switched from each prostaglandin analog/timolol combination at 3 months. *Lat--TFC* latanoprost/timolol combination, *PGA--TFC* prostaglandin analogs and timolol, *Tra--TFC* travoprost/timolol combination

Among the 439 patients, 240 patients instilled Taf--TFC in the morning (before 12:00) and 33 patients used it in the evening (after 16:00). The baseline mean IOP was 17.2 ± 5.0 mmHg (*n* = 240) in patients with morning dosing and 17.3 ± 4.3 mmHg (*n* = 33) in patients with evening dosing. With morning administration of Taf--TFC, IOP was reduced significantly to 14.2--14.7 mmHg (2.7--3.1 mmHg, 12.8--15.3% decrease), while evening dosing of Taf--TFC significantly reduced the IOP to 14.1--14.5 mmHg (2.4--3.9 mmHg, 12.3--20.4% decrease) (Fig. [9](#Fig9){ref-type="fig"}).Fig. 9IOP changes with morning dosing (before noon) or evening dosing (after 4 pm). *IOP* intraocular pressure

Adherence {#Sec9}
---------

Patient-reported adherence to Taf--TFC therapy was generally good. As a comparison to prior medication, we have analyzed data on 316 patients, whose data of both prior medication and self-reported adherence were available. Among these 316 patients, only 6 patients (1.9%) answered that compliance with medication was worse at 3 months than with prior medication. The percentage of patients who answered that compliance was improved was similar in the "switched" group and the "concomitant" group (20.4% and 19.5%, respectively). The number of medications resulted in patient adherence to medication being improved (Fig. [10](#Fig10){ref-type="fig"}).Fig. 10Adherence to tafluprost/timolol fixed combination compared with previous medication

Discussion {#Sec10}
==========

This is the first report on post-marketing surveillance of Taf--TFC (Tapcom combination ophthalmic solution) and the first clinical data for Taf--TFC obtained in the real clinical setting since its launch. In brief, Taf--TFC reduced IOP and was well tolerated over a short period.

The majority of patients in this study had NTG or POAG, accounting for more than 80% of the subjects combined. The Tajimi Study, an epidemiological study conducted in Japan by the Japan Glaucoma Society, found that 72% of glaucoma patients had NTG \[[@CR8], [@CR9]\]. Almost half of the glaucoma patients in our study had NTG, also showing that NTG is common among Japanese glaucoma patients. Besides patients with NTG, POAG, and OH, our study included patients with PACG, who have not been thoroughly investigated in previous clinical trials. Taf--TFC significantly reduced IOP in patients with NTG, POAG, and OH, and it also tended to reduce IOP in PACG patients. These results suggest that Taf--TFC is effective for treating a wide variety of types of glaucoma in actual clinical practice.

In this study, the incidence of ADR was 5.01%, which was lower than in previous interventional clinical studies \[[@CR6], [@CR7]\]. This may have been related to differences in the extent of clinical monitoring for adverse events between an interventional clinical study and daily clinical practice. In this study, serious ADRs were observed in two patients. While uncommon, serious ADRs must be considered when starting Taf--TFC. The incidence of ADRs in this study was also lower than that reported in a post-marketing study of Lat--TFC in Japan (9.9%) \[[@CR10]\]. Since this interim report only covers a 3-month period, the incidence of ADRs might increase later, and thus the overall safety of Taf--TFC should be concluded after this study have been completed.

In this study, Taf--TFC significantly reduced the IOP. In the Japanese phase III clinical study, the efficacy of Taf--TFC was significantly greater than that of tafluprost monotherapy \[[@CR6]\] or timolol monotherapy \[[@CR7]\], and was non-inferior to that of tafluprost combined with timolol \[[@CR6]\]. In this study, the reduction of IOP in patients switched from PGA monotherapy or β-blocker monotherapy was similar to that seen in the phase III studies, confirming superior efficacy of Taf--TFC over PGA or β-blocker monotherapy in this real-world study. Previous studies have shown that some patients exhibit a poor response to various PGAs \[[@CR11]--[@CR13]\]. Some reports indicate that poor responders to one PGA might respond to another PGA \[[@CR13]--[@CR15]\]. In this study, there were no obvious differences of the IOP reduction between patients switched from tafluprost, latanoprost, or travoprost, indicating that Taf--TFC reduces the IOP in patients previously treated with any PGA. Switching to Taf--TFC from another PGA--TFC (Lat--TFC or Tra--TFC) also significantly reduced the IOP, but switching to Taf--TFC from combined PGA and β-blocker therapy did not significantly reduce and maintain the IOP. In general, although fixed combinations usually have clinical equivalence to unfixed combinations, slight differences in IOP-lowering efficacy may be seen in some cases. It is sometimes assumed that the IOP-lowering effect of fixed combination drugs is weaker than concomitant use of the individual active ingredients, because the daily dose of one active ingredient is decreased. The difference of the IOP reduction noted in patients switched from other PGA--TFCs or concomitant PGA and β-blocker therapy suggests that the IOP-lowering effect of other PGA--TFC therapy is weaker than that of concomitant PGA and β-blocker therapy. However, once daily Taf--TFC was reported to show non-inferiority to concomitant use of tafluprost (once daily) and timolol (twice daily) \[[@CR6]\]. Thus, this study confirmed the phase III clinical results in the daily clinical setting. The formulation of Taf--TFC ophthalmic solution was designed to obtain similar penetration of timolol into the anterior chamber as with once daily timolol gel-forming solution, and this was achieved by adjusting the pH \[[@CR16]\]. Penetration of timolol into the anterior chamber is pH dependent and increases with an increase in pH, because timolol is a basic compound. Indeed, penetration of timolol into the anterior chamber was greater after instillation of Taf--TFC than after a single dose of timolol, and almost equal to that obtained with timolol gel-forming solution \[[@CR16]\]. This increased penetration of timolol into the anterior chamber with Taf--TFC may explain why its IOP-lowering effect is equal to that of concomitant PGA and β-blocker therapy, which may not be the case for all PGA--TFCs. There was also a significant IOP-lowering effect when patients were switched from other PGA--TFCs, with a mean IOP reduction of about 1.5 mmHg. Clinically, reduction of the IOP by 1 mmHg is considered to be significant, because the Early Manifest Glaucoma Trial (ClinicalTrials.gov identifier, NCT00000132) revealed an estimated 10% decrease in the risk of progression for each 1 mm of mercury reduction in IOP \[[@CR17]\].

The question about dosing time of PGA--TFCs is under debate. Timolol is recommended to be used in the morning, because the IOP-lowering effect of timolol maleate is weaker with dosing at night compared to that with daytime dosing \[[@CR18]\]. On the other hand, the IOP-lowering effect of PGAs does not change throughout the day \[[@CR18]\] and most physicians prefer to dose them in the evening. In addition, the theory on which dosing time is better for PGA--TFCs is still controversial. Takmaz reported that while both morning and evening dosing of Lat--TFC were effective for lowering the IOP, evening dosing was more effective than morning dosing in terms of IOP fluctuation \[[@CR19]\]. In contrast, there were no differences reported between morning and evening dosing of Lat--TFC \[[@CR20]\] and Tra--TFC \[[@CR21]\]. Although no large-scale comparison on the effect of the dosing time is available, the results of this study indicate that both morning and evening dosing for Taf--FDC can be utilized.

Adherence to glaucoma medication is an unsolved problem. In principle, treatment of glaucoma should start with monotherapy using a first-line drug followed by addition of a second-line drug or switching to a fixed combination according to many glaucoma guidelines (Japan Glaucoma Society, European Glaucoma Society, etc.). Concomitant use of two or more ophthalmic solutions may reduce adherence compared to monotherapy \[[@CR22]\], and the physician must evaluate whether a patient is likely to adhere to complicated treatment regimen. Prescription of a fixed combination is an alternative to two different drugs. In this study, adherence to Taf--TFC was generally good, and only six patients (1.9%) reported that compliance was worse than to previous medication. Djafari concluded that the use of fewer medications may improve adherence \[[@CR22]\]. In this study, the compliance rate showed the greatest improvement in patients who decreased the number of separate medications, but the improvement in compliance was not prominent.

Fixed combination drugs are not the first choice for treating glaucoma except for patients with a high risk for progression or for patients with a severe disease. In this study, some patients started their medication with Taf--TFC. The treatment pattern of Taf--TFC was not significantly different for glaucoma type, age, baseline IOP, and baseline MD values. However, patients who started with Taf--TFC tended to have NTG, were 30--39 years old, had a baseline IOP of 25 mmHg or higher, and had an MD value exceeding −6 dB. This information about "Naïve" patients receiving Taf--TFC monotherapy may be useful for physicians when selecting medication.

There were several limitations in this study. The major limitation of the study is the very short-term data. Unlike an interventional study, there was no control group, and specified examination and drug compliance could not be controlled in this observational study. Since we cannot define further the diagnosis of POAG and NTG, the SD of IOP reduction in this study was larger than in previous interventional studies, such as the phase III clinical trial of Taf--TFC \[[@CR6]\]. Despite these limitations, these data reflect the actual real-world usage of Taf--TFC, and thus, our findings can serve as a reference for assessing the future use of Taf--TFC in clinical practice. Even though this study only analyzed short-term data up to 3 months, our results suggest that Taf--TFC is effective for the treatment of glaucoma in a variety of clinical settings. Since glaucoma usually requires chronic treatment, both long-term efficacy and safety data need to be collected and analyzed. This up to 2-year observational study is still ongoing, and the long-term findings will be presented after the data have been analyzed at the end of the study period.

Conclusion {#Sec11}
==========

Evaluation of the short-term results obtained during 3 months after starting Taf--TFC treatment demonstrated that Taf--TFC is effective for a wide variety of glaucoma types or OH when administered in actual clinical practice with controllable or recoverable adverse reactions. Taf--TFC was effective regardless of regimens, and particularly, Taf--TFC significantly reduced IOP in patients insufficiently controlled on prior monotherapy.
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